SRF acquires Kanpur Plastipack's CPP business to bolster offerings
The deal, which is expected to be in the range of ₹100 crore, will enable SRF to expand and complement its existing offerings ...
KPL: Sisamau crowned champions
Kanpur: Sisamau Super Kings emerged as champions of the first Kanpur Premier League, defeating strong contender Mayur ...
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst
Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances ...
Kiniksa issues updates on abiprubart, KPL-387, mavrilimumab
Kiniksa Pharmaceuticals (NASDAQ:KNSA) plans to discontinue development of its drug abiprubart for the treatment of Sjögren’s disease and advance KPL-387 into mid-stage testing for recurrent ...
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution
Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– KPL-387 Phase 2/3 clinical ...
Kanpur Premier League makes historic global broadcast debut
Kanpur: The Kanpur Premier League (KPL) established a new record and set a high benchmark of excellence on Sunday evening ...
Sportskeeda14d
Kanpur Premier League 2025: Full schedule, squads, match timings, and live-streaming details
The Kanpur Premier League (KPL), one of the largest city-based leagues in Kanpur, is set to take place from March 2 to March 11, 2025.
Nasdaq17d
Kiniksa Pharmaceuticals to Initiate Phase 2/3 Clinical Trial of KPL-387 for Recurrent Pericarditis in 2025, Discontinues Abiprubart Development
Kiniksa Pharmaceuticals is set to begin a Phase 2/3 clinical trial for its drug KPL-387, aimed at treating recurrent pericarditis, in mid-2025. The company has noted that data from the ongoing ...